{"id":"https://openalex.org/W2030108063","doi":"https://doi.org/10.1006/exnr.2000.7350","title":"Combined Use of the Adenosine A2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys","display_name":"Combined Use of the Adenosine A2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys","publication_year":2000,"publication_date":"2000-04-01","ids":{"openalex":"https://openalex.org/W2030108063","doi":"https://doi.org/10.1006/exnr.2000.7350","mag":"2030108063","pmid":"https://pubmed.ncbi.nlm.nih.gov/10739638"},"language":"en","primary_location":{"id":"doi:10.1006/exnr.2000.7350","doi":"https://doi.org/10.1006/exnr.2000.7350","is_oa":false,"landing_page_url":"https://doi.org/10.1006/exnr.2000.7350","pdf_url":null,"source":{"id":"https://openalex.org/S165592611","display_name":"Experimental Neurology","issn_l":"0014-4886","issn":["0014-4886","1090-2430"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Experimental Neurology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2030108063"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108389177","display_name":"Tomoyuki Kanda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Tomoyuki Kanda","raw_affiliation_strings":["Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., 1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8731, Japan","Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St. Thomas' School of Biomedical Sciences, Hodgkin Building, King's College London, Guy's Campus, London Bridge, London, SE1 1UL, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., 1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8731, Japan","institution_ids":[]},{"raw_affiliation_string":"Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St. Thomas' School of Biomedical Sciences, Hodgkin Building, King's College London, Guy's Campus, London Bridge, London, SE1 1UL, United Kingdom","institution_ids":["https://openalex.org/I183935753"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Michael J. Jackson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Michael J. Jackson","raw_affiliation_strings":["Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St. Thomas' School of Biomedical Sciences, Hodgkin Building, King's College London, Guy's Campus, London Bridge, London, SE1 1UL, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St. Thomas' School of Biomedical Sciences, Hodgkin Building, King's College London, Guy's Campus, London Bridge, London, SE1 1UL, United Kingdom","institution_ids":["https://openalex.org/I183935753"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103517453","display_name":"Lance A. Smith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Lance A. Smith","raw_affiliation_strings":["Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St. Thomas' School of Biomedical Sciences, Hodgkin Building, King's College London, Guy's Campus, London Bridge, London, SE1 1UL, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St. Thomas' School of Biomedical Sciences, Hodgkin Building, King's College London, Guy's Campus, London Bridge, London, SE1 1UL, United Kingdom","institution_ids":["https://openalex.org/I183935753"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112017104","display_name":"R. K. B. Pearce","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Ronald K.B. Pearce","raw_affiliation_strings":["Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St. Thomas' School of Biomedical Sciences, Hodgkin Building, King's College London, Guy's Campus, London Bridge, London, SE1 1UL, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St. Thomas' School of Biomedical Sciences, Hodgkin Building, King's College London, Guy's Campus, London Bridge, London, SE1 1UL, United Kingdom","institution_ids":["https://openalex.org/I183935753"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110183513","display_name":"Joji Nakamura","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joji Nakamura","raw_affiliation_strings":["Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd. 1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8731, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd. 1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8731, Japan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022951213","display_name":"Hiroshi Kase","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hiroshi Kase","raw_affiliation_strings":["Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd. 1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8731, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd. 1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8731, Japan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111713786","display_name":"Yoshihisa Kuwana","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Yoshihisa Kuwana","raw_affiliation_strings":["Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St. Thomas' School of Biomedical Sciences, Hodgkin Building, King's College London, Guy's Campus, London Bridge, London, SE1 1UL, United Kingdom","Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd. 1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8731, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St. Thomas' School of Biomedical Sciences, Hodgkin Building, King's College London, Guy's Campus, London Bridge, London, SE1 1UL, United Kingdom","institution_ids":["https://openalex.org/I183935753"]},{"raw_affiliation_string":"Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd. 1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8731, Japan","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5105511214","display_name":"Peter G. Jenner","orcid":"https://orcid.org/0009-0006-0327-7584","observed_orcids":["https://orcid.org/0009-0006-0327-7584"]},"institutions":[{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Peter Jenner","raw_affiliation_strings":["Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St. Thomas' School of Biomedical Sciences, Hodgkin Building, King's College London, Guy's Campus, London Bridge, London, SE1 1UL, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St. Thomas' School of Biomedical Sciences, Hodgkin Building, King's College London, Guy's Campus, London Bridge, London, SE1 1UL, United Kingdom","institution_ids":["https://openalex.org/I183935753"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4110,"currency":"USD","value_usd":4110},"apc_paid":null,"fwci":8.4425,"has_fulltext":false,"cited_by_count":250,"citation_normalized_percentile":{"value":0.98274985,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"162","issue":"2","first_page":"321","last_page":"327"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9735999703407288,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9735999703407288,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10919","display_name":"Deep Brain Stimulation and Movement Disorders","score":0.005100000184029341,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.004900000058114529,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/adenosine-a2a-receptor-antagonist","display_name":"adenosine A2A receptor antagonists","score":0.9829999804496765},{"id":"https://openalex.org/keywords/l-dopa","display_name":"L-DOPA","score":0.9079999923706055},{"id":"https://openalex.org/keywords/quinpirole","display_name":"quinpirole","score":0.9229999780654907},{"id":"https://openalex.org/keywords/mptp-induced-parkinsonism","display_name":"MPTP-induced parkinsonism","score":0.8420000076293945},{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":0.7680000066757202},{"id":"https://openalex.org/keywords/dyskinesia","display_name":"dyskinesia","score":0.8370000123977661},{"id":"https://openalex.org/keywords/motor-impairment","display_name":"motor impairment","score":0.8090000152587891},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6620000004768372},{"id":"https://openalex.org/keywords/locomotor-activity","display_name":"locomotor activity","score":0.7049999833106995},{"id":"https://openalex.org/keywords/marmoset","display_name":"marmoset","score":0.7559999823570251}],"concepts":[{"id":"https://openalex.org/C2778296116","wikidata":"https://www.wikidata.org/wiki/Q253187","display_name":"Quinpirole","level":4,"score":0.9056494235992432},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.68675297498703},{"id":"https://openalex.org/C2780405171","wikidata":"https://www.wikidata.org/wiki/Q629444","display_name":"Dyskinesia","level":4,"score":0.6650148630142212},{"id":"https://openalex.org/C2778674702","wikidata":"https://www.wikidata.org/wiki/Q239816","display_name":"MPTP","level":4,"score":0.6277644634246826},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.5998370051383972},{"id":"https://openalex.org/C137183658","wikidata":"https://www.wikidata.org/wiki/Q461076","display_name":"Dopaminergic","level":3,"score":0.5415980219841003},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.5360802412033081},{"id":"https://openalex.org/C44208683","wikidata":"https://www.wikidata.org/wiki/Q15335165","display_name":"Dopamine receptor D2","level":3,"score":0.5318828225135803},{"id":"https://openalex.org/C199596767","wikidata":"https://www.wikidata.org/wiki/Q21110872","display_name":"Dopamine receptor D3","level":4,"score":0.45468616485595703},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.44299745559692383},{"id":"https://openalex.org/C2778491162","wikidata":"https://www.wikidata.org/wiki/Q3063865","display_name":"Adenosine A2A receptor","level":5,"score":0.4196772277355194},{"id":"https://openalex.org/C2779734285","wikidata":"https://www.wikidata.org/wiki/Q11085","display_name":"Parkinson's disease","level":3,"score":0.3435722589492798},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2670822739601135},{"id":"https://openalex.org/C67907053","wikidata":"https://www.wikidata.org/wiki/Q356147","display_name":"Adenosine receptor","level":4,"score":0.25054463744163513},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.22953251004219055},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.08604374527931213}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002144","descriptor_name":"Callithrix","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002230","descriptor_name":"Carbidopa","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004195","descriptor_name":"Disease Models, Animal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004357","descriptor_name":"Drug Synergism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004409","descriptor_name":"Dyskinesia, Drug-Induced","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007274","descriptor_name":"Injections, Intraperitoneal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007980","descriptor_name":"Levodopa","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007980","descriptor_name":"Levodopa","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009043","descriptor_name":"Motor Activity","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D010302","descriptor_name":"Parkinson Disease, Secondary","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D010302","descriptor_name":"Parkinson Disease, Secondary","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010302","descriptor_name":"Parkinson Disease, Secondary","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D015632","descriptor_name":"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017447","descriptor_name":"Receptors, Dopamine D1","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D017448","descriptor_name":"Receptors, Dopamine D2","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":false},{"descriptor_ui":"D019257","descriptor_name":"Quinpirole","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D043705","descriptor_name":"Receptor, Adenosine A2A","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058915","descriptor_name":"Purinergic P1 Receptor Antagonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1006/exnr.2000.7350","doi":"https://doi.org/10.1006/exnr.2000.7350","is_oa":false,"landing_page_url":"https://doi.org/10.1006/exnr.2000.7350","pdf_url":null,"source":{"id":"https://openalex.org/S165592611","display_name":"Experimental Neurology","issn_l":"0014-4886","issn":["0014-4886","1090-2430"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Experimental Neurology","raw_type":"journal-article"},{"id":"pmid:10739638","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10739638","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Experimental neurology","raw_type":"Journal Article"},{"id":"pmh:oai:kclpure.kcl.ac.uk:publications/eb1e308d-89fb-4c3b-807a-04df7a4ad94c","doi":null,"is_oa":false,"landing_page_url":"https://kclpure.kcl.ac.uk/portal/en/publications/eb1e308d-89fb-4c3b-807a-04df7a4ad94c","pdf_url":null,"source":{"id":"https://openalex.org/S4306400216","display_name":"Research Portal (King's College London)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I183935753","host_organization_name":"King's College London","host_organization_lineage":["https://openalex.org/I183935753"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Kanda, T, Jackson, M J, Smith, L A, Pearce, R K B, Nakamura, J, Kase, H, Kuwana, Y & Jenner, P 2000, 'Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys', Experimental Neurology, vol. 162, no. 2, pp. 321 - 327. https://doi.org/10.1006/exnr.2000.7350","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":38,"referenced_works":["https://openalex.org/W47813478","https://openalex.org/W99762335","https://openalex.org/W1886164324","https://openalex.org/W1977181604","https://openalex.org/W1981480470","https://openalex.org/W1982686544","https://openalex.org/W1998013279","https://openalex.org/W2007037518","https://openalex.org/W2014477753","https://openalex.org/W2016597162","https://openalex.org/W2016947344","https://openalex.org/W2034588648","https://openalex.org/W2036056358","https://openalex.org/W2042809317","https://openalex.org/W2049152829","https://openalex.org/W2050351659","https://openalex.org/W2051049259","https://openalex.org/W2063911036","https://openalex.org/W2070194750","https://openalex.org/W2073963693","https://openalex.org/W2083868750","https://openalex.org/W2088525880","https://openalex.org/W2092175068","https://openalex.org/W2097719090","https://openalex.org/W2100100055","https://openalex.org/W2100528361","https://openalex.org/W2122614848","https://openalex.org/W2125030626","https://openalex.org/W2130570136","https://openalex.org/W2136306454","https://openalex.org/W2255064238","https://openalex.org/W2429469062","https://openalex.org/W2950888084","https://openalex.org/W4206634583","https://openalex.org/W4235730787","https://openalex.org/W4236396139","https://openalex.org/W4244194205","https://openalex.org/W6691995134"],"related_works":["https://openalex.org/W2034588648","https://openalex.org/W2026475932","https://openalex.org/W4376139292","https://openalex.org/W4367841323","https://openalex.org/W2131371182","https://openalex.org/W2030257205","https://openalex.org/W2111597060","https://openalex.org/W1998013279","https://openalex.org/W1992289692","https://openalex.org/W2088619016"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":10},{"year":2017,"cited_by_count":10},{"year":2016,"cited_by_count":8},{"year":2015,"cited_by_count":8},{"year":2014,"cited_by_count":14},{"year":2013,"cited_by_count":9},{"year":2012,"cited_by_count":13}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}